Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes

被引:0
|
作者
Santini, Valeria [1 ]
机构
[1] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, Largo Brambilla 3, I-50134 Florence, Italy
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷 / 08期
关键词
Inflammation; MDS; Methylation; Somatic mutations; Targeted therapy; ACUTE MYELOID-LEUKEMIA; PROGNOSTIC SCORING SYSTEM; DRIVER SOMATIC MUTATIONS; CLONAL HEMATOPOIESIS; OPEN-LABEL; CLINICAL-IMPLICATIONS; ELDERLY-PATIENTS; PHASE-I; THERAPY; ANEMIA;
D O I
10.1016/j.clml.2018.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS. The research devoted to clarifying the mechanisms of action and mechanisms of resistance to hypomethylating agents has also advanced, mostly resulting from different approaches to the study of DNA methylation. Recent observations have reinforced support for targeted therapies for selected subgroups of MDS patients. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:495 / 500
页数:6
相关论文
共 50 条
  • [1] "Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL
    Chiaretti, Sabina
    Jabbour, Elias
    Hoelzer, Dieter
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (05): : 301 - 310
  • [2] SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes
    Volpe, Virginia O.
    Garcia-Manero, Guillermo
    Komrokji, Rami S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (03): : 168 - 177
  • [3] SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
    Hochman, Michael J.
    DeZern, Amy E.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : 573 - 582
  • [4] SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
    Sallman, David A.
    Tanaka, Tiffany N.
    List, Alan
    Bejar, Rafael
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : 613 - 620
  • [5] SOHO State of the Art Updates and Next Questions: Myelofibrosis
    Pettit, Kristen
    Verstovsek, Srdan
    Talpaz, Moshe
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 191 - 199
  • [6] SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes
    Aubrey, Brandon J.
    Brunner, Andrew M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (12): : 869 - 877
  • [7] SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies
    Forsberg, Mark
    Konopleva, Marina
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 1 - 14
  • [8] SOHO State of the Art Updates and Next Questions: IDH Inhibition
    Dragani, Matteo
    de Botton, Stephane
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (09): : 567 - 572
  • [9] SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma
    Watkins, Marcus P.
    Fanale, Michelle A.
    Bartlett, Nancy L.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (02): : 81 - 90
  • [10] New Series: SOHO 'State of the Art Updates and Next Questions'
    Kantarjian, Hagop
    Talpaz, Moshe
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (08): : 463 - 463